ClinicalTrials.govcontrolled
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breas
ClinicalTrials.gov study NCT04622319. IPD Sharing: YES. Countries: 31. Publications: 1.
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8